From: Elevated levels of arginase activity are related to inflammation in patients with COPD exacerbation
Group (I)a | Group (II)a | Group (III)a | Group (IV)a | p I + II | p I + III | p II + III | p III + IV | p I + IV | |
---|---|---|---|---|---|---|---|---|---|
Age (years) | 67.67 (10.34) | 69.37 (8.65) | 71.40 (11.34) | 70.64 (11.37) | 0.605 | 0.467 | 0.717 | 0.859 | 0.557 |
BMI (kg/m2) | 28.67 (5.94) | 28.14 (3.74) | 25.45 (3.100) | 25.36 (3.375) | 0.752 | 0.076 | 0.036 | 0.943 | 0.032 |
Pack-year | 39.14 (20.25) | 59.06 (25.91) | 51.73 (20.00) | 52.21 (20.67) | 0.082 | 0.185 | 0.426 | 0.950 | 0.378 |
CAT | 7.47 (3.58) | 13.53 (4.41) | 15.73 (3.45) | 17.14 (3.439) | < 0.001 | < 0.001 | 0.016 | 0.281 | 0.122 |
mMRC < 2b | 15 (23.8%) | 5 (7.9%) | 1 (1.60%) | 2 (3.2%) | < 0.001b | < 0.001b | 0.002b | 0.770b | 0.002b |
mMRC ≥ 2b | 0 (0%) | 14 (22.2%) | 14 (22.2%) | 12 (19.00%) | |||||
FEV1pb (%) | 121.40 (19.88) | 58.15 (21.87) | 47.51 (13.87) | 76.09 (21.37) | < 0.001 | < 0.001 | 0.157 | 0.932 | 0.111 |
FEV1/FVCpb | 81.05 (6.322) | 48.06 (12.10) | 45.64 (11.14) | 47.53 (9.199) | < 0.001 | < 0.001 | 0.892 | 0.624 | 0.553 |
Dlco (%) | 93.96 (24.71) | 81.21 (22.55) | 68.49 (14.26) | 59.39 (11.57) | 0.133 | < 0.001 | 0.001 | 0.125 | 0.155 |
FeNO (ppb) | 25.86 (16.41) | 17.93 (23.31) | 14.30 (8.455) | 13.20 (6.704) | 0.289 | 0.016 | 0.424 | 0.809 | 0.796 |